TY - CHAP M1 - Book, Section TI - Superficial Fungal Infections A1 - Brown, Thomas E. R. A1 - Dresser, Linda D. A2 - DiPiro, Joseph T. A2 - Talbert, Robert L. A2 - Yee, Gary C. A2 - Matzke, Gary R. A2 - Wells, Barbara G. A2 - Posey, L. Michael PY - 2017 T2 - Pharmacotherapy: A Pathophysiologic Approach, 10e AB - Patient Care Process for Vulvovaginal CandidiasisCollectPatient Characteristics (age, pregnancy status)Patient medical history (previous vaginal infections, diabetes mellitus)Social history (sexual activity)Current Meds (oral contraceptives, antibiotics)AssessSymptoms consistent with VVC (itching, clumpy white vaginal discharge)Absence of fever, pelvic pain, colored or foul smelling vaginal dischargePossibility of sexually transmitted diseaseRecurrence of symptoms from previous vaginal infectionPlanRemove predisposing risk factors if possibleSelect a drug therapy regimen including specific antifungal(s) dose, route, frequency, and duration (Table 120-2)Education of the patient regarding causes of VVC and the selected treatmentReferral to other health care providers if complicated or recurrent VVC or risk factors for sexually transmitted diseaseImplementProvide patient counselling (avoid harsh soaps, perfumes, hot tub use, contraceptive use)Keep vaginal area clean and dry avoid constrictive clothingSelf-assessment of symptom relief is appropriateFollow-up: Monitor and EvaluateMonitor for complete resolution of symptoms within 24-48 hrs of initiation of therapy (itching, clumpy white discharge)Determine the presence of adverse effects (nausea, abdominal discomfort, vaginal irritation)Refer to other health care provider if symptoms do not resolve despite adherence SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1154962453 ER -